FDA, EMA Consider Natalizumab as First Line in MSFDA, EMA Consider Natalizumab as First Line in MS

Biogen Idec and Elan announced they have submitted applications in the United States and Europe for an expanded indication for natalizumab as first-line therapy for anti-JCV antibody-negative MS. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news